Chronic activation of AMP-activated kinase as a strategy for slowing aging

Medical Hypotheses

Volumn 63, Issue 2, 2004, Pages 334-339

  McCarty, Mark F ^a  

^a NutriGuard Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; PHENFORMIN; RAF PROTEIN; RAS PROTEIN; RECEPTOR BLOCKING AGENT; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 1;

AGING; CALORIC RESTRICTION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LOCALIZATION; ENZYME METABOLISM; EXPERIMENTAL MOUSE; GLUCOSE TRANSPORT; HORMONAL REGULATION; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; LACTIC ACIDOSIS; LIVER FUNCTION; MUSCLE LEVEL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SYNTHESIS; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

EID: 3242777031     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.01.043     Document Type: Article

References (56)

1. Bartke A., Chandrashekar V., Dominici F., Turyn D., Kinney B., Steger R., et al. Insulin-like growth factor-1 (IGF-1) and aging: controversies and new insights. Biogerontology. 4:2003;1-8
2. Longo V.D., Finch C.E. Evolutionary medicine: from dwarf model systems to healthy centenarians? Science. 299:2003;1342-1346
3. Brown-Borg H.M. Hormonal regulation of aging and life span. Trends Endocrinol. Metab. 14:2003;151-153
4. McCarty M.F. A low-fat, whole-food vegan diet, as well as other strategies that down-regulate IGF-I activity, may slow the human aging process. Med. Hypotheses. 60:2003;784-792
5. Ngo T.H., Barnard R.J., Tymchuk C.N., Cohen P., Aronson W.J. Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States). Cancer Causes Control. 13:2002;929-935
6. Evans G.W., Meyer L.K. Life span is increased in rats supplemented with a chromium-pyridine-2-carboxylate complex. Adv. Sci. Res. 1:1994;19-23
7. McCarty M.F. Homologous physiological effects of phenformin and chromium picolinate. Med. Hypotheses. 41:1993;316-324
8. Parr T. Insulin exposure and aging theory. Gerontology. 43:1997;182-200
9. Hardie D.G., Carling D. The AMP-activated protein kinase-fuel gauge of the mammalian cell? Eur. J. Biochem. 246:1997;259-273
10. Corton J.M., Gillespie J.G., Hawley S.A., Hardie D.G. 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229:1995;558-565
11. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108:2001;1167-1174
12. Musi N., Hirshman M.F., Nygren J., Svanfeldt M., Bavenholm P., Rooyackers O., et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 51:2002;2074-2081
13. Hawley S.A., Gadalla A.E., Olsen G.S., Hardie D.G. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes. 51:2002;2420-2425
14. Fryer L.G., Parbu-Patel A., Carling D. The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277:2002;25226-25232
15. Zheng D., MacLean P.S., Pohnert S.C., Knight J.B., Olson A.L., Winder W.W., et al. Regulation of muscle GLUT-4 transcription by AMP-activated protein kinase. J. Appl. Physiol. 91:2001;1073-1083
16. Jessen N., Pold R., Buhl E.S., Jensen L.S., Schmitz O., Lund S. Effects of AICAR and exercise on insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscles. J. Appl. Physiol. 94:2003;1373-1379
17. De L.V., la Marca A., Orvieto R., Morgante G. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85:2000;1598-1600
18. Fruehwald-Schultes B., Oltmanns K.M., Toschek B., Sopke S., Kern W., Born J., et al. Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism. 51:2002;531-536
19. da S.X., Leclerc X., Varadi I., Tsuboi A., Moule T., Rutter S.K. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem. J. 371:2003;761-774
20. Phillips L.S., Goldstein S., Pao C.I. Nutrition and somatomedin. XXVI. Molecular regulation of IGF-I by insulin in cultured rat hepatocytes. Diabetes. 40:1991;1525-1530
21. Baxter R.C. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res. 42:1994;140-144
22. Lewitt M.S. Stimulation of IGF-binding protein-1 secretion by AMP-activated protein kinase. Biochem. Biophys. Res. Commun. 282:2001;1126-1131
23. Stumvoll M., Nurjhan N., Perriello G., Dailey G., Gerich J.E. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333:1995;550-554
24. Fontbonne A., Charles M.A., Juhan-Vague I., Bard J.M., Andre P., Isnard F., et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care. 19:1996;920-926
25. Lee A., Morley J.E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes. Res. 6:1998;47-53
26. Pasquali R., Gambineri A., Biscotti D., Vicennati V., Gagliardi L., Colitta D., et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 85:2000;2767-2774
27. Kay J.P., Alemzadeh R., Langley G., D'Angelo L., Smith P., Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 50:2001;1457-1461
28. Mogul H.R., Peterson S.J., Weinstein B.I., Zhang S., Southren A.L. Metformin and carbohydrate-modified diet: a novel obesity treatment protocol: preliminary findings from a case series of nondiabetic women with midlife weight gain and hyperinsulinemia. Heart Dis. 3:2001;285-292
29. Sim A.T., Hardie D.G. The low activity of acetyl-CoA carboxylase in basal and glucagon-stimulated hepatocytes is due to phosphorylation by the AMP-activated protein kinase and not cyclic AMP-dependent protein kinase. FEBS Lett. 233:1988;294-298
30. Winder W.W., Wilson H.A., Hardie D.G., Rasmussen B.B., Hutber C.A., Call G.B., et al. Phosphorylation of rat muscle acetyl-CoA carboxylase by AMP-activated protein kinase and protein kinase A. J. Appl. Physiol. 82:1997;219-225
31. Rouru J., Pesonen U., Koulu M., Huupponen R., Santti E., Virtanen K., et al. Anorectic effect of metformin in obese Zucker rats: lack of evidence for the involvement of neuropeptide Y. Eur. J. Pharmacol. 273:1995;99-106
32. Flechtner-Mors M., Ditschuneit H.H., Jenkinson C.P., Alt A., Adler G. Metformin inhibits catecholamine-stimulated lipolysis in obese, hyperinsulinemic, hypertensive subjects in subcutaneous adipose tissue: an in situ microdialysis study. Diabetic Med. 16:1999;1000-1006
33. Salt I.P., Connell J.M., Gould G.W. 5-Aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. Diabetes. 49:2000;1649-1656
34. Abbasi F., Carantoni M., Chen Y.D., Reaven G.M. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care. 21:1998;1301-1305
35. Frayn K.N. Non-esterified fatty acid metabolism and postprandial lipaemia. Atherosclerosis. 141(Suppl 1):1998;S41-S46
36. Kolodziejczyk B., Duleba A.J., Spaczynski R.Z., Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil. Steril. 73:2000;1149-1154
37. Kim J., Yoon M.Y., Choi S.L., Kang I., Kim S.S., Kim Y.S., et al. Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway. J. Biol. Chem. 276:2001;19102-19110
38. Bolster D.R., Crozier S.J., Kimball S.R., Jefferson L.S. AMP-activated protein kinase suppresses protein synthesis in rat skeletal muscle through down-regulated mammalian target of rapamycin (mTOR) signaling. J. Biol. Chem. 277:2002;23977-23980
39. Kimura N., Tokunaga C., Dalal S., Richardson C., Yoshino K., Hara K., et al. A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signalling pathway. Genes Cells. 8:2003;65-79
40. Cheng S.W., Fryer L.G., Carling D., Shepherd P.R. T2446 is a novel mTOR phosphorylation site regulated by nutrient status. J. Biol. Chem. 2004
41. Bonni A., Brunet A., West A.E., Datta S.R., Takasu M.A., Greenberg M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription- dependent and -independent mechanisms. Science. 286:1999;1358-1362
42. Panwalkar A., Verstovsek S., Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer. 100:2004;657-666
43. Harada H., Andersen J.S., Mann M., Terada N., Korsmeyer S.J. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc. Natl. Acad. Sci. USA. 98:2001;9666-9670
44. Dilman V.M., Anisimov V.N. Effect of treatment with phenformin, diphenylhydantoin or L-dopa on life span and tumour incidence in C3H/Sn mice. Gerontology. 26:1980;241-246
45. Vasil'eva I.A., Bershtein L.M., Ostroumova M.N., Dil'man V.M. [Effect of phenformin and miscleron on the blood somatomedin activity level in breast cancer]. Vopr. Onkol. 26:1980;34-36
46. Dilman V.M., Berstein L.M., Zabezhinski M.A., Alexandrov V.A., Bobrov J.F., Pliss G.B. Inhibition of DMBA-induced carcinogenesis by phenformin in the mammary gland of rats. Arch. Geschwulstforsc. 48:1978;1-8
47. Dean, W. Metformin: an effective and underappreciated life extension drug; 2003 [Report]
48. Sato R., Goldstein J.L., Brown M.S. Replacement of serine-871 of hamster 3-hydroxy-3-methylglutaryl-CoA reductase prevents phosphorylation by AMP-activated kinase and blocks inhibition of sterol synthesis induced by ATP depletion. Proc. Natl. Acad. Sci. USA. 90:1993;9261-9265
49. Morrow V.A., Foufelle F., Connell J.M., Petrie J.R., Gould G.W., Salt I.P. Direct activation of AMP-activated protein kinase stimulates nitric oxide synthesis in human aortic endothelial cells. J. Biol. Chem. 2003
50. Ruderman N.B., Cacicedo J.M., Itani S., Yagihashi N., Saha A.K., Ye J.M., et al. Malonyl-CoA and AMP-activated protein kinase (AMPK): possible links between insulin resistance in muscle and early endothelial cell damage in diabetes. Biochem. Soc. Trans. 31:2003;202-206
51. Furstenberger G., Senn H.J. Insulin-like growth factors and cancer. Lancet Oncol. 3:2002;298-302
52. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346:2002;393-403
53. Kent, S. BioMarker Pharmaceuticals develops anti-aging therapy; 2003 [Report]
54. Krentz A.J., Ferner R.E., Bailey C.J. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety. 11:1994;223-241
55. El Mir M.Y., Nogueira V., Fontaine E., Averet N., Rigoulet M., Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 275:2000;223-228
56. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348(Pt 3):2000;607-614